Clinical Trial · NCT02232685

Whole Body Bone Scan vs 18F-Choline PET/CT in Prostate Cancer

Overview

Prostate cancer is currently the leading newly diagnosed cancer in the industrialized world. Treatment of prostate cancer is highly dependent on the stage of the disease. Current methods for staging are known to be inaccurate. Prior studies from our department suggest that PET/CT is useful in staging of bone metastases in patients with prostate cancer. The aim of this study is to test the usefulness of Choline PET/CT for the staging of bone metastases compared to current standard methods in patients with newly diagnosed prostate cancer. Better initial staging will result in better treatment of the individual patient. If we are able to develop a more accurate method of staging patients with undetected metastases on current staging will be spared of the side-effects associated with current treatment - impotence, incontinence, radiation damage etc.

Sponsor

Odense University Hospital

Phase

N/A

ClinicalTrials.gov

NCT02232685

Drug / Compound

choline

Isotope(s):

Target(s):

Phospholipid Metabolism

Ligand Class: Small Molecules

methylene diphosphonate

Isotope(s):

Target(s):

Bone Metabolism

Ligand Class: Small Molecules

Eligibility

Inclusion

Written consent and
cT-stage ≥ cT2c
PSA ≥ 20 ng/mL and/or
Newly diagnosed, histologically verified PCa and
Gleason score \> 6 and/or

Exclusion

Withdrawal of consent or
Other active malign disease